|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,145.00 JPY | -0.09% |
|
-0.02% | +2.48% |
| 06-26 | Lupin Receives U.S. FDA Tentative Approval for Enzalutamide Tablets | MT |
| 06-24 | Merck Wins European Commission Approval for KEYTRUDA Plus Padcev in Bladder Cancer | MT |
| Market Cap | 3,843B 23.77B 20.84B 19.21B 17.99B 33.73B 2,242B 34.43B 231B 89.35B 1,108B 89.26B 87.31B | P/E 2027 * |
11.1x | P/E 2028 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 3,766B 23.3B 20.43B 18.83B 17.63B 33.05B 2,197B 33.74B 226B 87.56B 1,086B 87.47B 85.56B | EV / Sales 2027 * |
1.67x | EV / Sales 2028 * | 1.66x |
| Free-Float |
98.88% | Yield 2027 * |
3.75% | Yield 2028 * | 3.87% |
Last Transcript: Astellas Pharma Inc.
| 1 day | -0.09% | ||
| 1 week | -0.02% | ||
| Current month | -6.04% | ||
| 1 month | -3.96% | ||
| 3 months | -15.38% | ||
| 6 months | +2.19% | ||
| Current year | +2.48% |
| 1 week | 2,122 |  | 2,181 |
| 1 month | 2,041 | | 2,283 |
| Current year | 2,041 | | 2,717 |
| 1 year | 1,365 | | 2,717 |
| 3 years | 1,243.5 | | 2,717 |
| 5 years | 1,243.5 | | 2,717 |
| 10 years | 1,243.5 | | 2,717 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 10/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 01/11/2023 |
Tatjana Dragovic
CMP | Compliance Officer | - | 01/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 10/02/2023 |
Naoki Okamura
BRD | Director/Board Member | 63 | 01/06/2019 |
| Director/Board Member | 58 | 01/06/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.09% | -0.02% | +54.87% | -2.01% | 23.77B | |
| +7.13% | +9.97% | +51.94% | +166.83% | 1,077B | |
| +3.99% | +11.50% | +67.53% | +55.63% | 613B | |
| +4.20% | +17.03% | +35.63% | +87.74% | 448B | |
| +0.99% | +4.85% | +27.93% | +22.82% | 332B | |
| +1.82% | +8.19% | +41.15% | +26.80% | 293B | |
| +0.22% | +6.75% | +31.51% | +42.02% | 286B | |
| +0.73% | +8.53% | -26.22% | -40.85% | 215B | |
| +1.56% | +6.14% | +28.38% | +59.45% | 193B | |
| +3.26% | +3.33% | +18.83% | +67.03% | 159B | |
| Average | +1.85% | +7.20% | +33.16% | +48.55% | 363.98B | |
| Weighted average by Cap. | +2.25% | +8.87% | +40.61% | +80.74% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,249B 13.91B 12.2B 11.24B 10.53B 19.74B 1,312B 20.15B 135B 52.29B 649B 52.24B 51.1B | 2,079B 12.86B 11.28B 10.4B 9.73B 18.25B 1,213B 18.63B 125B 48.35B 600B 48.3B 47.24B |
| Net income | 346B 2.14B 1.88B 1.73B 1.62B 3.03B 202B 3.1B 20.78B 8.04B 99.73B 8.03B 7.86B | 327B 2.02B 1.78B 1.64B 1.53B 2.87B 191B 2.93B 19.67B 7.61B 94.38B 7.6B 7.44B |
| Net Debt | -76.82B -475M -417M -384M -360M -674M -44.83B -688M -4.62B -1.79B -22.15B -1.78B -1.75B | -391B -2.42B -2.12B -1.96B -1.83B -3.43B -228B -3.5B -23.51B -9.1B -113B -9.09B -8.89B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/06/26 | ¥2,145.00 | -0.09% | 6,216,800 |
| 25/06/26 | ¥2,147.00 | -0.58% | 4,672,000 |
| 24/06/26 | ¥2,159.50 | +1.24% | 5,998,200 |
| 23/06/26 | ¥2,133.00 | -2.02% | 6,256,400 |
| 22/06/26 | ¥2,177.00 | +1.47% | 5,402,600 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
Select your edition
All financial news and data tailored to specific country editions
